ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PODD Insulet Corporation

166.50
-11.03 (-6.21%)
11 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Insulet Corporation NASDAQ:PODD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -11.03 -6.21% 166.50 163.00 176.50 193.30 162.715 181.87 3,176,414 05:00:02

Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference

13/02/2024 9:01pm

Business Wire


Insulet (NASDAQ:PODD)
Historical Stock Chart


From Feb 2024 to May 2024

Click Here for more Insulet Charts.

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at The Raymond James & Associates 45th Annual Institutional Investors Conference in Orlando on Tuesday, March 5, 2024 at 11:35 a.m. (Eastern Time).

To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available following the event.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone or the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation.

Investor Relations:

Deborah R. Gordon Vice President, Investor Relations (978) 600-7717 dgordon@insulet.com

Media:

Angela Geryak Wiczek Senior Director, Corporate Communications (978) 932-0611 awiczek@insulet.com

1 Year Insulet Chart

1 Year Insulet Chart

1 Month Insulet Chart

1 Month Insulet Chart

Your Recent History

Delayed Upgrade Clock